BIOMARKER:

KIF5B-RET fusion

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	RXDX-105 Sensitive: C3 – Early Trials RXDX-105 Sensitive : C3	RXDX-105 Sensitive: C3 – Early Trials RXDX-105 Sensitive : C3
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3
KIF5B-RET fusion	Lung Cancer	KIF5B-RET fusion	Lung Cancer	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3
KIF5B-RET fusion	Lung Adenocarcinoma	KIF5B-RET fusion	Lung Adenocarcinoma	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	selpercatinib Resistant: C4 – Case Studies selpercatinib Resistant : C4	selpercatinib Resistant: C4 – Case Studies selpercatinib Resistant : C4
KIF5B-RET fusion	Lung Adenocarcinoma	KIF5B-RET fusion	Lung Adenocarcinoma	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	cabozantinib tablet Resistant: C4 – Case Studies cabozantinib tablet Resistant : C4	cabozantinib tablet Resistant: C4 – Case Studies cabozantinib tablet Resistant : C4
KIF5B-RET fusion	Lung Adenocarcinoma	KIF5B-RET fusion	Lung Adenocarcinoma	cabozantinib tablet Sensitive: D – Preclinical cabozantinib tablet Sensitive : D	cabozantinib tablet Sensitive: D – Preclinical cabozantinib tablet Sensitive : D
KIF5B-RET fusion	Lung Adenocarcinoma	KIF5B-RET fusion	Lung Adenocarcinoma	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D
KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: D – Preclinical pralsetinib Sensitive : D	pralsetinib Sensitive: D – Preclinical pralsetinib Sensitive : D